C5 and atypical hemolytic-uremic syndrome: Several other antibodies targeting C5 are also being developed; for example, LFG316 targets C5 in age-related macular degeneration [49], while Mubodina is used to treat atypical hemolytic-uremic syndrome (aHUS) [50].